OneAlphaMed identified, scored, and activated 250+ Digital Opinion Leaders across social platforms to drive pre-launch disease awareness for a novel dermatology biologic — before a single sales rep made a call.
Industry / Specialty
Pharmaceutical & Healthcare
Scale / Audience
15,000+ HCPs
Core Solutions
Co-created Certification
Time to Value
Pan-India Deployment
Stop funding clicks. Start building undisputed credibility for your brand today.
A blockbuster cholesterol-lowering medication in its eighth year on market had reached commercial stagnation — declining prescription volumes despite an unchanged clinical profile and a still-substantial untreated patient population. The brand’s commercial model had become a victim of its own success: the same high-decile prescribers were being called on repeatedly, while thousands of mid-decile, high-potential cardiologists and internists were effectively invisible to the field force. OneAlphaMed deployed a predictive micro-segmentation model that redefined the brand’s target universe, identified 15,000 previously under-served high-value prescribers, and delivered a precision content strategy that reactivated the brand’s growth trajectory within two quarters.
Brands that have been on market for 5+ years face a specific commercial trap: their data models are optimized for the prescribers they already know, making it structurally difficult to find growth in new audiences.
The brand's existing CRM segmentation was based on historical prescription decile — a retrospective model that identified who had already been prescribing, not who was most likely to increase prescribing. This approach systematically under-prioritized newly qualified specialists, practice-changers in growing suburban markets, and internists managing high-cholesterol patients who had never received a meaningful brand engagement.
The top-decile cardiologists who formed the core of the existing call universe had been receiving identical clinical messaging for 3-5 years. Sales rep visit logs showed sharply declining engagement scores among this group — declining meeting duration, declining detail acceptance, and declining clinical question frequency — all indicators of deep promotional fatigue with both the brand and its standard messaging.
With no new clinical data, no label update, and no significant market event, the brand team was unable to articulate a compelling reason why the field force should re-engage with a drug that prescribers considered well-understood. Without a new commercial narrative, any reactivation attempt risked being perceived as purely quota-driven rather than clinically valuable.
OneAlphaMed built a forward-looking prescriber intelligence model that identified hidden growth opportunities the brand's existing data architecture was structurally designed to miss.
OneAlphaMed's analytics team integrated the brand's CRM data with external datasets — regional cardiovascular event rates, practice setting growth indicators, new specialist registration data, and digital engagement behavioral signals — to build a composite prescriber opportunity score. This model ranked 15,000 previously low-priority HCPs as high-potential growth targets based on future prescribing likelihood rather than historical behavior.
The 15,000 newly identified targets were clustered into five behaviorally distinct prescriber micro-segments — each with a unique clinical orientation, digital engagement pattern, and motivational profile. OneAlphaMed developed a distinct content strategy and messaging hierarchy for each persona, ensuring that every engagement felt clinically relevant and personally calibrated rather than generic promotional.
Rather than simply handing the new target list to the field force, OneAlphaMed designed a coordinated activation sequence: digital content pre-warming via precision email and WhatsApp, followed by MSL-led scientific outreach for the highest-potential segment, followed by field rep engagement — ensuring that every first conversation started with an informed, engaged physician rather than a cold contact.
From Retrospective Deciles to Predictive Intelligence.
The fundamental innovation was replacing a backward-looking segmentation model — who has prescribed — with a forward-looking opportunity model — who will prescribe next, and why. This shift from historical data to predictive intelligence is not merely a methodological improvement; it represents a complete reconception of how mature brand teams should define their target universe, allocate their resources, and measure their commercial performance.
The micro-segmentation engine identified and converted a previously invisible growth universe — restoring prescription momentum without any change to the product's clinical profile.
The reactivation program demonstrated that commercial plateau for a mature brand is not inevitable — it is a data and strategy problem with a systematic solution.
Experienced a qualitatively different engagement with the brand — receiving precisely relevant clinical content calibrated to their specific patient population and prescribing context rather than the generic promotional messaging that had made them disengage from previous interactions. Several newly engaged HCPs subsequently became active scientific advocates for the brand within their local peer networks.
Gained a genuinely energizing commercial mandate — a validated new universe of high-potential, receptive prescribers — that restored motivation and performance metrics that had been steadily declining under the stagnant call-the-same-decile-1-prescribers model. Rep engagement scores and manager-assessed performance ratings both improved significantly within the first two quarters of the reactivation program.
Achieved a documented reversal of the prescription decline trend — moving from -3% quarterly volume growth to +28% within two quarters — without a product reformulation, label update, or price change. The segmentation model itself has since been institutionalized as the brand team's standard commercial planning infrastructure for all future planning cycles.
The model integrates specialty board certification databases, regional disease burden and epidemiological data, practice setting growth indicators (new clinic registrations, insurance panel expansions), digital engagement behavioral data (email open and click history, webinar attendance records), and publicly available medical publication and conference activity data. All data integration is conducted under formal data sharing agreements and in full compliance with applicable privacy regulations.
Each of the five prescriber personas is translated into a simple, memorable field-facing brief — a single primary message, two supporting clinical talking points, and one tailored leave-behind tool. The complexity of the underlying data model is entirely absorbed in the pre-call planning layer; the rep simply executes a clear, well-defined conversation script calibrated to the individual HCP's persona profile.
Yes, with modifications. For brands facing generic competition, the micro-segmentation model additionally incorporates payer formulary position data, patient affordability indicators, and brand loyalty behavioral signals to identify the specific prescriber segments where branded prescribing remains commercially viable. We have successfully applied this approach to brands up to 15 years post-launch.
+91 9811660635
info@onealphamed.com
2414, Ground Floor, Aravali Vihar, Sector 49 Faridabad, Haryana – 121001 India
Copyright © 2026 OneAlphaMed. All Rights Reserved.